Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301

Eyegate Pharmaceuticals, Inc. Announces Closing of Initial Public Offering of Approximately $4,100,000 of Common Stock

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced initial public offering of 683,250 shares of its common stock at a price to the public of $6.00 per share. The gross proceeds to EyeGate from this offering are approximately$4,100,000 before deducting underwriting discounts and other estimated offering expenses. EyeGate has granted the representative of the underwriters a 45-day option to purchase up to 102,487 additional shares of its common stock to cover over-allotments, if any.

Aegis Capital Corp. and Chardan Capital Markets, LLC acted as the joint book-running managers for the offering.

A registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) was declared effective on February 12, 2015.

The offering was made by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18thFloor, New York, NY 10019, telephone: 212-813-1010, email: Investors may also obtain these documents at no cost by visiting the SEC’s website at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyeGate

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. For more information, please visit

CONTACT: Lee Roth / Joseph Green
         The Ruth Group for Eyegate Pharmaceuticals
         646-536-7012 / 7013 /

Eyegate Pharmaceuticals, Inc.